Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 4, 2004 - Issue 5
Submit an article Journal homepage
110
Views
31
CrossRef citations to date
0
Altmetric
Drug Profile

Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting

Rudolph M Navari Walther Cancer Research Center, 250 Nieuwland Science Hall, University of Notre Dame, Notre Dame, IN 46556, USA. [email protected]
Pages 715-724 | Published online: 10 Jan 2014

REFERENCES

  • Navari RM. Pathogenesis-based treatment of chemotherapy induced nausea and vomiting: two new agents. I Support. Oncol. 1,89–103 (2003).
  • ••Current review of chemotherapy-inducednausea and vomiting (CINV).
  • Kris MG. Why do we need another anti-emetic?I Clin. Oncol. 21,4077–4080 (2003).
  • Berger AM, Clark-Snow RA. Adverse effects of treatment. In: Principles and ffactice of Oncology Devita VT Jr, Heiman S, Rosenberg S (Eds), Lippincott Williams & Wilkins, PA, USA, 2869–2880 (2001).
  • Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. Clin. Oncol. 15,103–109 (1997).
  • Koeller JM, Aapro MS, Gralla RJ et al Anti-emetic guidelines: creating a more practical treatment approach. Support. Cam Cancer 10, 517–518 (2002).
  • •Guidelines for CINV.
  • Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 18,163–173 (2000).
  • Simpson K, Spencer CM, McClellan KJ. Topisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs59,1297–1315 (2000).
  • Taguchi T, Tsukamoto F, Watanabe T et al Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho 26,1163–1170 (1999).
  • Kimura E, Niimi E, Watanabe A etal. Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho 23,477–481 (1996).
  • Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists. Ann. Phalmacother. 37,1276-1286 (2003).
  • The Italian Group for Anti-emetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Eng. I Med. 342,1554–1559 (2000).
  • Hickok JT, Roscoe JA, Morrow GR et al Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 anti-emetics. Cancer97, 2880–2886 (2003).
  • •Summarizes the limitations of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists in controlling delayed CINV.
  • Eisenberg P, MacKintosh FR, Pitch P et al. Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann. Oncol. 15,330–337 (2004).
  • Eisenberg P, Figueroa-Vadillo J, Zamora R et al Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Results of a Phase III, single-dose trial versus dolasetron. Cancer 98, 2473–2482 (2003).
  • •Data used for approval of palonosetron.
  • Gralla R, Lichinitser M, Van der Vegt S et al Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol. 14,1570–1577 (2003).
  • •Data used for approval of palonosetron.
  • Aapro MS, Bertoli L, Lordick F et al. Palonosetron is effective in preventing acute and delayed chemotherapy induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support. Care Cancer11,391 (2003) (Abstract 17).
  • •Data used for the approval of palonosetron.
  • Cartmell AD, Ferguson S, Yanagihara R et al Protection against chemotherapy-induced nausea and vomiting is maintained over multiple cycles of moderately or highly emetogenic chemotherapy by palonosetron, a potent 5-HT3 receptor antagonist. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 3041).
  • Diemunsch P, Grelot L. Potential of substance P antagonists as anti-emetics. Drugs60, 533–546 (2000).
  • ••Review of neurokinin-1 receptorantagonists and their potential use as antiemetics.
  • Watson JW, Gonsalves SF, Rossa AA et al The anti-emetic effects of CP-99,994 in the ferret and dog: role of the NK-1 receptor. Br. Pharmacol 115, 84–94 (1998).
  • Fasth KJ, Bergstrom M, Kilpatrick G et al Brain uptake and receptor binding of two C11 labeled selective high affinity NK-1 antagonists GR203040 and GR205171. .1. Label. Compounds Radiopharm. 40, 665–667 (1997).
  • Tattersall FD, Rycroft W, Francis B et al. Tachykinins NK-1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology35, 1121–1129 (1996).
  • Minami M, Endo T, Yokoda H et al Effects of CP-99,994, a tachykinin NK-1 receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK-1 and 5-HT3 receptors. Eur. Phalmacol 428, 215–220 (2001).
  • Tattersall FD, Rycroft W, Cumberbatch M et al The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology39, 652–663 (2000).
  • Blum RA, Majumdar AK, McCrea JB et al Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin. flier. 25, 1407–1419 (2003).
  • Feuring M, Lee Y, Orlowski LH et al Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects. Clin. Pharmacol 43, 912–917 (2003).
  • McCrea JB, Majumdar AK, Goldberg MR et al Effects of the neurokinin-1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin. Pharmacol Pier. 74, 17–24 (2003).
  • Majumdar AK, McCrea JB, Panebianco DL et al Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin. Pharmacol Pier. 74, 150–156 (2003).
  • Kris MG, Radford JE, Pizzo BA et al Use of a NK1 receptor antagonist to prevent delayed emesis after cisplatin (letter). I Natl Cancer Inst. 89, 817–818 (1997).
  • Cocquyt V, Van Belle S, Reinhardt RR et al Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur. Cancer 37, 835–842 (2001).
  • Navari RM, Reinhardt RR, Gralla RJ et al Reduction of cisplatin-induced emesis by a selective neurokin-1 receptor antagonist. N. Engl. Med. 340, 190–195 (1999).
  • Hesketh PJ, Gralla RJ, Webb RT et al Randomized Phase II study of the neurokinin-1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. j Clin. Oncol 17, 338–343 (1999).
  • Van Belle S, Liechinitser M, Navari RM et al Prevention of cisplatin- induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-0869. Cancer94, 3032–3041 (2002).
  • Campos D, Pereira JR, Reinhardt RR et al Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.j Clin. Oncol 19, 1759–1767 (2001).
  • Chawla SP, Grunberg SM, Gralla RJ et al Establishing the dose of the oral NK-1 antagonist aprepitant for chemotherapy induced nausea and vomiting. Cancer 97, 2290–2300 (2003).
  • Hesketh PJ, Grunberg SM, Gralla RJ et al The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind placebo-controlled trial in patients receiving high-dose cisplatin — aprepitant protocol 052 study group. Clin. Oncol 21, 4112–4119 (2003).
  • •Data used for the approval of aprepitant.
  • Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al Addition of the neurokinin-1 receptor antagonist aprepitant to standard anti-emetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer 97, 3090–3098 (2003).
  • •Data used for the approval of aprepitant.
  • De Witt R, Herrstedt J, Rapoport BL et al Addition of the oral NK1 antagonist aprepitant to standard anti-emetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J: Clin. Oncol 21, 4105–4111 (2003).
  • De Witt R, Herrstedt J, Rapoport B et al The oral NK-1 antagonist, aprepitant, given with standard anti-emetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled Phase III clinical trials. Eur .1. Cancer 40, 403–410 (2004).
  • Warr DG, Eisenberg P, Hesketh PJ et al Phase III double-blind study to assess an aprepitant-containing regimen for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy. Proc. Am. Soc. Clin. Oncol (2004) (Abstract 8007).
  • ••Data on the use of aprepitant in patientsreceiving moderately emetogenic chemotherapy.
  • Grunberg SM, Deuson R, Mavros P et al Incidence of chemotherapy-induced nausea and emesis after modem anti-emetics: perception versus reality. Cancer 100, 2261–2268 (2004).
  • Fabi A, Barduagni M, Lauro S et al Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support. Cam Cancer 11, 156–161 (2003).
  • Navari RM, Einhom LH, Loehrer PJ et al A Phase II trial of olanzapine for the prevention of chemotherapy induced nausea and vomiting. Proc. Am Soc. Clin. Oncol (2004) (Abstract 8046).
  • •Use of olanzapine to control CINV.
  • Guttuso T, Roscoe J, Griggs J. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet361, 1703–1705 (2003).
  • •Use of gabapentin for the control of CINV.

Websites

  • Merck & Co., Inc. Emend (aprepitant) capsules: prescribing information. USA online www.merck.com (Accessed September 2004)
  • ••Prescribing information and potentialtoxicities and adverse events of aprepitant.
  • NCCN Clinical Practice Guidelines in Oncology: antiemesis, version 1 (2004) www.nccn.org (Accessed September 2004)
  • ••2004 guidelines for the prevention of CINV.
  • MASCC Antiemetic Consensus Conference, Perugia, Italy (March 29–31, 2004) www.mascc.org (Accessed September 2004)
  • •2004 guidelines for the prevention of CINV.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.